Costs of deep foot infections in patients with diabetes mellitus.

abstract：:Potential conflict between the goals of the investigators and the sponsors of pharmacoeconomic and clinical research has been well documented. Although there have been efforts to formalise relationships between sponsors and investigators in some areas of clinical research, no set of guidelines or standardised contract...

journal_title：PharmacoEconomics

authors： Schulman KA,Rubenstein LE,Glick HA,Eisenberg JM

更新日期：1995-03-01 00:00:00

abstract：:A number of health-related QOL (HR-QOL) measures specifically designed for people with diabetes mellitus have appeared in the literature. This article provides a selective review of 12 measures that address this important construct. For each included study, a description of the measure and its development phase is pro...

journal_title：PharmacoEconomics

authors： Watkins K,Connell CM

更新日期：2004-01-01 00:00:00

abstract：:There are insufficient resources in the UK to fund all new technologies and new indications approved by the National Institute for Health and Clinical Excellence (NICE). Diverting funding from existing sources will have a detrimental effect on the provision of other priority services. The UK Office of Fair Trading (OF...

journal_title：PharmacoEconomics

authors： Godman B,Haycox A,Schwabe U,Joppi R,Garattini S

更新日期：2008-01-01 00:00:00

abstract：:As a consequence of its prevalence, early onset and chronicity, schizophrenia imposes clinical and economic impediments to healthcare practitioners and society alike. Among the many antipsychotics available to treat the symptoms of this devastating illness, clozapine has emerged and differentiated itself from the othe...

journal_title：PharmacoEconomics

authors： Tse G,Thompson D,Procyshyn RM

更新日期：2003-01-01 00:00:00

abstract：:Darunavir boosted by low-dose ritonavir (DRV/r), at a daily dose of 600/100 mg twice a day (bid), has been shown to be superior to alternative highly active antiretroviral therapy (HAART) regimens for the management of treatment-experienced, HIV-infected adults in the phase IIb POWER trials and the phase III TITAN tri...

journal_title：PharmacoEconomics

authors： Mauskopf J,Annemans L,Hill AM,Smets E

更新日期：2010-01-01 00:00:00

abstract：:Migraine headache is responsible for significantly more healthcare resource and lost labour costs than previously reported. Costs associated with migraine were assessed via a survey conducted in 940 patients, 70% of whom responded. All met the International Headache Society's diagnostic criteria for migraine and had ...

journal_title：PharmacoEconomics

authors： Osterhaus JT,Gutterman DL,Plachetka JR

更新日期：1992-07-01 00:00:00

abstract：:Deterministic sensitivity analyses (DSA) remain important to interpret the effect of uncertainties in individual parameters on results of cost-effectiveness analyses. Classic DSA methodologies may lead to wrong conclusions due to a lack of or misleading information regarding marginal effects, non-linearity, likelihood...

journal_title：PharmacoEconomics

authors： Vreman RA,Geenen JW,Knies S,Mantel-Teeuwisse AK,Leufkens HGM,Goettsch WG

更新日期：2021-01-01 00:00:00

abstract：BACKGROUND:Heart failure (HF) is a well-recognized public health concern and imposes high economic and societal costs. Decision analytic models exist for evaluating the economic ramifications associated with HF. Despite this, studies that appraise these modelling approaches for augmenting best-practice decisions remain...

journal_title：PharmacoEconomics

authors： Di Tanna GL,Bychenkova A,O'Neill F,Wirtz HS,Miller P,Ó Hartaigh B,Globe G

更新日期：2019-03-01 00:00:00

abstract：:A number of recent findings from the literature imply that the value of a QALY varies depending on the concentration or dispersion of that QALY over treated individuals. Given that funding decisions are currently made under either the assumption of distributive-neutrality or some combination of explicit decision crite...

journal_title：PharmacoEconomics

authors： Mortimer D

更新日期：2006-01-01 00:00:00

abstract：INTRODUCTION:Mixture modelling is increasingly being considered where a potential cure leads to a long life. Traditional methods use relative survival models for frail populations or cure models that have improper survival functions with theoretical infinite lifespans. Additionally, much of the work uses population dat...

journal_title：PharmacoEconomics

authors： Grant TS,Burns D,Kiff C,Lee D

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease associated with increasing morbidity and mortality and an economic burden that stretches beyond the patient to healthcare systems. Avoiding exacerbations and subsequent hospitalizations is an important clinical aim and ca...

journal_title：PharmacoEconomics

authors： Mittmann N,Hernandez P,Mellström C,Brannman L,Welte T

更新日期：2011-05-01 00:00:00

abstract：:The purpose of this study was to establish the incidence of surgical amputation for critical leg ischaemia in New Zealand, and estimate the hospital, prostheses and indirect costs of this intervention. The cost of amputations was then compared with the cost of treating such patients with iloprost. The study was retr...

journal_title：PharmacoEconomics

authors： Scott HM,Scott WG

更新日期：1994-08-01 00:00:00

abstract：BACKGROUND:While drotrecogin alfa (activated) was shown to decrease absolute 28-day mortality by 6.1% in patients with severe sepsis in the Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study, no mortality benefit was observed in the subset of patients with only one organ system failure. C...

journal_title：PharmacoEconomics

authors： Betancourt M,McKinnon PS,Massanari RM,Kanji S,Bach D,Devlin JW

更新日期：2003-01-01 00:00:00

abstract：:In an effort to control escalating health expenditures, especially in hospitals, many countries are planning or experimenting with prospective budgeting systems. Belgium is no exception and has recently introduced, with some success, limited fixed charges per hospital admission and/or per hospitalisation day for labor...

journal_title：PharmacoEconomics

authors： Closon MC,Crott R,Even-Adin D

更新日期：1996-03-01 00:00:00

abstract：BACKGROUND:The COUGAR-02 trial recently showed survival and quality-of-life benefits of docetaxel and active symptom control (DXL + ASC) over active symptom control (ASC) alone in patients with refractory oesophagogastric adenocarcinoma. AIM:The aim of this study was to conduct an economic evaluation conforming to Nat...

journal_title：PharmacoEconomics

authors： Meads DM,Marshall A,Hulme CT,Dunn JA,Ford HE

更新日期：2016-01-01 00:00:00

abstract：:The National Institute for Health and Care Excellence (NICE) invited Pfizer, the manufacturer of inotuzumab ozogamicin (henceforth inotuzumab), to submit clinical- and cost-effectiveness evidence for inotuzumab as part of NICE's single technology appraisal process. The Centre for Reviews and Dissemination and the Cent...

journal_title：PharmacoEconomics

authors： Cox E,Wade R,Peron M,Dietz KC,Eastwood A,Palmer S,Griffin S

更新日期：2019-09-01 00:00:00

abstract：:We have defined the effect and acceptability of a locally developed general practice programme for the modification of prescribing. This voluntary programme consisted of prescription analysis and feedback, followed by visits from a pharmacist, a therapeutic bulletin on benzodiazepine prescribing, and use of a locally ...

journal_title：PharmacoEconomics

authors： Ferguson RI,Salmond CE,Maling TJ

更新日期：1995-06-01 00:00:00

abstract：:Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the relief of the symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), sprains and strains, sports injuries and menstrual disorders, and have a small role in the management of patent ductus arteriosus in the neonate. In patients with RA, symptom...

journal_title：PharmacoEconomics

authors： Wynne HA,Campbell M

更新日期：1993-02-01 00:00:00

abstract：:A survey of the prescribing of psychotropic drugs was carried out at the Psychiatric Hospital of Bahrain. This retrospective study on 60 inpatients of the Long Stay Ward revealed a man:woman ratio of 2.7. 91% of the men and 88% of the women were over 40 years old. 44 of the 60 patients had a diagnosis of schizophre...

journal_title：PharmacoEconomics

authors： El Hefny F,Al Haddad MK,Mathur V

更新日期：1992-03-01 00:00:00

abstract：:Our objective was to assess the quality of reporting of original economic research articles in PharmacoEconomics from inception to the end of 1995, in order to identify areas of strength and weakness, and analyse trends over time. Each regular issue of the journal was examined for original economic evaluations. Accept...

journal_title：PharmacoEconomics

authors： Iskedjian M,Trakas K,Bradley CA,Addis A,Lanctôt K,Kruk D,Ilersich AL,Einarson TR

更新日期：1997-12-01 00:00:00

abstract：:Although decision making about what drugs to include in an institutional formulary appears to lend itself readily to quantitative techniques such as decision analysis and cost-benefit analysis, a review of the literature reveals that very little has been published in this area. Several of the published decision analy...

journal_title：PharmacoEconomics

authors： Schechter CB

更新日期：1993-06-01 00:00:00

abstract：:In the current climate of cost containment and quality control, nosocomial infection is a worrisome adverse event in hospital care. Hospitalised patients require care for increasingly severe illnesses, and are therefore more susceptible to infection, especially by opportunistic micro-organisms. It is thus necessary to...

journal_title：PharmacoEconomics

authors： Gálvez-Vargas R,Bueno-Cavanillas A,García-Martín M

更新日期：1995-02-01 00:00:00

abstract：OBJECTIVE:Pertussis is a highly contagious infection affecting mainly children. Acellular pertussis vaccines were recently introduced in Canada based on evidence of improved safety and efficacy over whole cell vaccines, the current standard of care. The following study reports the economic impact of replacing the whole...

journal_title：PharmacoEconomics

authors： Iskedjian M,Einarson TR,O'Brien BJ,De Serres JG,Gold R,Gemmill IM,Milkovich N,Rosner A

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:Before the new round of healthcare reform in China, primary healthcare providers could obtain a fixed 15 % or greater mark-up of profits by prescribing and selling medicines. There were concerns that this perverse incentive was a key cause of irrational medicine use. China's new Essential Medicines Program (...

journal_title：PharmacoEconomics

authors： Chen M,Wang L,Chen W,Zhang L,Jiang H,Mao W

更新日期：2014-03-01 00:00:00

abstract：:The use of pharmacoeconomic tools has grown dramatically in the past decade as provision of healthcare throughout the industrialised world has required increased cost consciousness. However, pharmacoeconomic analysis has not yet been fully exploited as a conceptual underpinning for public or private health policy deci...

journal_title：PharmacoEconomics

authors： Greenberg PE,Arcelus A,Birnbaum HG,Cremieux PY,LeLorier J,Ouellette P,Slavin MB

更新日期：1999-11-01 00:00:00

abstract：BACKGROUND:The ARTEMIS trial compared first-line antiretroviral therapy (ART) with lopinavir/ritonavir (LPV/r) to darunavir plus ritonavir (DRV + RTV) for HIV-1-infected subjects. In order to fully assess the implications of this study, economic modelling extrapolating over a longer term is required. OBJECTIVE:The aim...

journal_title：PharmacoEconomics

authors： Simpson KN,Pei PP,Möller J,Baran RW,Dietz B,Woodward W,Migliaccio-Walle K,Caro JJ

更新日期：2013-05-01 00:00:00

abstract：:Rheumatoid arthritis (RA) is a chronic, generally progressive autoimmune disease that causes functional disability, significant pain and joint destruction, and leads to premature mortality. It is estimated to affect between 0.5 and 1.0% of the adult population worldwide, increases in prevalence with age and affects mo...

journal_title：PharmacoEconomics

authors： Kvien TK

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Health-related quality of life (HRQoL) is a key outcome in cost-utility analyses, which are commonly used to inform healthcare decisions. Different instruments exist to evaluate HRQoL, however while some jurisdictions have a preferred system, no gold standard exists. Standard meta-analysis struggles with the...

journal_title：PharmacoEconomics

authors： Schmitz S,Makovski TT,Adams R,van den Akker M,Stranges S,Zeegers MP

更新日期：2020-01-01 00:00:00

abstract：:Mapping functions are estimated using regression analyses and are frequently used to predict health state utility values (HSUVs) in decision analytic models. Mapping functions are used when evidence on the required preference-based measure (PBM) is not available, or where modelled values are required for a decision an...

journal_title：PharmacoEconomics

authors： Ara R,Rowen D,Mukuria C

更新日期：2017-12-01 00:00:00

abstract：:The lack of a uniform costing methodology is often considered a weakness of economic evaluations that hinders the interpretation and comparison of studies. Standardisation is therefore an important topic within the methodology of economic evaluations and in national guidelines that formulate the formal requirements fo...

journal_title：PharmacoEconomics

authors： Oostenbrink JB,Koopmanschap MA,Rutten FF

更新日期：2002-01-01 00:00:00